Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2/3 1

Status

Completed 8Terminated 6Recruiting 4Active not recruiting 4Withdrawn 1Unknown 1Not yet recruiting 1Available 1

Sponsor Class

OTHER 11INDUSTRY 6NETWORK 5NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Urinary Bladder Neoplasms 4Carcinoma, Transitional Cell 4Non-Muscle Invasive Bladder Neoplasms 3Neoplasms 2Carcinoma in Situ 2Virus Diseases 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Neoplasms by Site 1Neoplasm Recurrence, Local 1Mycobacterium Infections 1Disease 1Adenoviridae Infections 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Mitomycin × Clear all
NCT02106572 2026-05-22

TIM

Abnoba Gmbh

Phase 3 Terminated
174 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04688931 2024-06-06

ATLAS

UroGen Pharma Ltd.

Phase 3 Terminated
282 enrolled 29 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated
22 enrolled
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT03335059 2020-04-15

RITE-USA

Medical Enterprises Ltd.

Phase 3 Terminated
5 enrolled
Genitourinary

Urinary Bladder Neoplasms, Disease

NCT02982395 2019-08-30

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Samyang Biopharmaceuticals Corporation

Phase 3 Terminated
36 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01200992 2017-08-24

EMBARC-RF

Bioniche Life Sciences Inc.

Phase 3 Terminated
84 enrolled 7 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡